Table 1.
Lymphoid immune responses to T. cruzi infection in different mouse models.
| Mouse | Parasite | Organ | Approach | Th1/Th2 | Treg | Th17 | References |
|---|---|---|---|---|---|---|---|
| BALB/c | Y | Heart | Low/Exacerbation | Cuervo et al., 2008 | |||
| BALB/c | Y | Heart | Low/Exacerbation | High/Exacerbation | Sanoja et al., 2013 | ||
| BALB/c | Tulahuén | Heart Spleen | Neutrophil depletion | Low/Exacerbation | Chen et al., 2001 | ||
| BALB/c | Y | Heart | Anti-CD25 | Limited role | Mariano et al., 2008 | ||
| BALB/c | H8 Yucatan | Spleen | rSSP4 immunization | rSSP4 specific/Exacerbation | Flores-García et al., 2013 | ||
| BALB/c | Y | Spleen Heart | Anti-IL-17 | High/Protective | da Matta Guedes et al., 2010 | ||
| BALB/c TS-CD4-Tg | Tulahuén | Spleen | Adoptive transfer of TS specific T cells into RAG KO | High/ Less protection | High/More protection | Cai et al., 2016 | |
| C57BL/6 | Y | Heart | High/Protection | Cuervo et al., 2008 | |||
| C57BL/6 | Y | Heart | High/Protection | High/Protection | High/Protection | Sanoja et al., 2013 | |
| C57BL/6 | Tulahuén | Heart Spleen | Neutrophil depletion | High/Protection | Chen et al., 2001 | ||
| C57BL/6 | Y | Spleen | Osteopontin antibody | High/Protection | High/Protection | Santamaría and Corral, 2013 | |
| C57BL/6 | Tulahuén | Spleen | Anti-IL-10 | NA | NA | NA | Silva et al., 1992 |
| C57BL/6 | Colombiana | Heart | IL-10 KO | NA | NA | NA | Roffê et al., 2012 |
| C57BL/6 | Tulahuén | Thymus periphery | Low/Exacerbation | González et al., 2016 | |||
| C57BL/6 | Colombian | Heart | G-CSF treatment | High/Protection | Vasconcelos et al., 2013 | ||
| C57BL/6 | Y | Heart | SOCS2 KO | Low/Protection pathology | Esper et al., 2012 | ||
| C57BL/6 | Tulahuén | Liver Heart Spleen | Ebi3 KO (classical Treg cells) | High/Protection | High/Protection | Böhme et al., 2016 | |
| C57BL/6 | Y | Heart | Ebi3 KO (Tr1 cells) | High/Protection | Medina et al., 2017 | ||
| C57BL/6 | Tulahuén | Spleen | High/Exacerbation | Low/Exacerbation | González et al., 2015 | ||
| C57BL/6 | Tulahuén | Spleen | IL-6 KO | NA | NA | NA | Gao and Pereira, 2002 |
| C57BL/6 | Tulahuén | Spleen | BATF2 KO | High/Protection | Kitada et al., 2017 | ||
| C57BL/6 | Tulahuén | Liver | IL-17A KO | High/Protection | Miyazaki et al., 2010 | ||
| C57BL/6 | Tulahuén | Spleen LN Liver | IL-17RA KO | High/Protection | Tosello Boari et al., 2012 | ||
| C3H/HeN | RA | Tc52/immunized | High/protection | High/protection | Matos et al., 2017 | ||
| C57BL/6 B6.SJL C3H/HeSnJ | Tulahuén | Muscle Brain Gut | Anti-CD25 | Limited role high/protect | Kotner and Tarleton, 2007 | ||
| C57BL/6 C3H/HeJ BALB/c | Colombian Y | Heart | Anti-CD25 | Limited role | Sales et al., 2008 | ||
| A/J | Brazil | Heart | Anti-CD25 | High/Exacerbation | Bonney et al., 2015 | ||
| Swiss Webster | Colombian | Anti-CD25 | High/Exacerbation | Nihei et al., 2014 | |||
| C3H | Sylvio X10/4 clone | Heart | G-CSF Benznidazol treatment | Low/Pathology | Medium/Pathology | High/Pathology | González et al., 2013 |
Mouse and parasite strain used; organ studied; approach used: infection of deficient mouse strain or knockout (KO), treatment, immunization, cell depletion, or adoptive transfer; Th1/Th2 balance Treg and Th17 responses (high medium or low)/effect (Protection, exacerbation or pathology) and references are indicated.